Department of Neurosurgery, Albany Medical College, Albany, New York.
J Neurosurg Spine. 2015 Aug;23(2):137-43. doi: 10.3171/2014.12.SPINE14477. Epub 2015 May 1.
OBJECT Anterior cervical discectomy and fusion (ACDF) is an effective procedure for the treatment of cervical radiculopathy and/or myelopathy; however, postoperative dysphagia is a significant concern. Dexamethasone, although potentially protective against perioperative dysphagia and airway compromise, could inhibit fusion, a generally proinflammatory process. The authors conducted a prospective, randomized, double-blinded, controlled study of the effects of steroids on swallowing, the airway, and arthrodesis related to multilevel anterior cervical reconstruction in patients who were undergoing ACDF at Albany Medical Center between 2008 and 2012. The objective of this study was to determine if perioperative steroid use improves perioperative dysphagia and airway edema. METHODS A total of 112 patients were enrolled and randomly assigned to receive saline or dexamethasone. Data gathered included demographics, functional status (including modified Japanese Orthopaedic Association myelopathy score, neck disability index, 12-Item Short-Form Health Survey score, and patient-reported visual analog scale score of axial and radiating pain), functional outcome swallowing scale score, interval postoperative imaging, fusion status, and complications/reoperations. Follow-up was performed at 1, 3, 6, 12, and 24 months, and CT was performed 6, 12, and 24 months after surgery for fusion assessment. RESULTS Baseline demographics were not significantly different between the 2 groups, indicating adequate randomization. In terms of patient-reported functional and pain-related outcomes, there were no differences in the steroid and placebo groups. However, the severity of dysphagia in the postoperative period up to 1 month proved to be significantly lower in the steroid group than in the placebo group (p = 0.027). Furthermore, airway difficulty and a need for intubation trended toward significance in the placebo group (p = 0.057). Last, fusion rates at 6 months proved to be significantly lower in the steroid group but lost significance at 12 months (p = 0.048 and 0.57, respectively). CONCLUSIONS Dexamethasone administered perioperatively significantly improved swallowing function and airway edema and shortened length of stay. It did not affect pain, functional outcomes, or long-term swallowing status. However, it significantly delayed fusion, but the long-term fusion rates remained unaffected. Clinical trial registration no.: NCT01065961 (clinicaltrials.gov).
颈椎前路椎间盘切除术和融合术(ACDF)是治疗颈椎神经根病和/或颈椎病的有效方法;然而,术后吞咽困难是一个严重的问题。地塞米松虽然有可能预防围手术期吞咽困难和气道阻塞,但可能会抑制融合,这是一个普遍的炎症过程。作者在 2008 年至 2012 年间在奥尔巴尼医疗中心对接受 ACDF 的患者进行了一项前瞻性、随机、双盲、对照研究,以评估类固醇对吞咽、气道和多节段颈椎前路重建相关融合的影响。本研究的目的是确定围手术期使用类固醇是否能改善围手术期吞咽困难和气道水肿。
共纳入 112 例患者,并随机分为生理盐水组或地塞米松组。收集的数据包括人口统计学资料、功能状态(包括改良日本矫形协会脊髓病评分、颈部残疾指数、12 项简明健康调查评分、患者报告的轴向和放射状疼痛的视觉模拟评分)、功能结果吞咽量表评分、术后间隔影像学、融合状态和并发症/再手术。随访时间为 1、3、6、12 和 24 个月,术后 6、12 和 24 个月进行 CT 评估融合情况。
两组患者的基线人口统计学资料无显著差异,表明随机分组充分。在患者报告的功能和疼痛相关结果方面,类固醇组和安慰剂组之间没有差异。然而,在术后 1 个月内,类固醇组的吞咽困难严重程度明显低于安慰剂组(p = 0.027)。此外,气道困难和需要插管在安慰剂组中也有趋势(p = 0.057)。最后,6 个月时类固醇组的融合率明显低于安慰剂组,但在 12 个月时失去了统计学意义(p = 0.048 和 0.57)。
围手术期给予地塞米松可显著改善吞咽功能和气道水肿,缩短住院时间。它对疼痛、功能结果或长期吞咽状况没有影响。然而,它显著延迟了融合,但长期融合率没有受到影响。临床试验注册号:NCT01065961(clinicaltrials.gov)。